Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHM-1101 in MMP2+ Recurrent or Progressive Glioblastoma Multiforme
NCT05627323Phase 1Terminated
- Sponsor
- Chimeric Therapeutics
- Start
- Jun 2023
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CHM-1101 in glioblastoma multiforme (GBM) (2 arms), sponsored by Chimeric Therapeutics. Primary endpoints: Dose-limiting toxicity at 28 days, Cytokine Release Syndrome up to 15 years and 1 more. Started Jun 2023; status: terminated.
02
Drugs
CHM-1101
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05627323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627323.